Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast Limited announced the quotation of 3,225,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) with the code MSB, effective from January 24, 2025. This issuance is a part of previously announced transactions, potentially enhancing the company’s financial flexibility and market standing.
More about Mesoblast Limited
Mesoblast Limited is a company operating within the biotechnology industry, specializing in the development of cellular medicines. The company’s primary focus is on regenerative medicine products that target major diseases with significant unmet medical needs.
YTD Price Performance: -9.09%
Average Trading Volume: 123,813
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.27B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.
